

**FISCAL IMPACT OF PROPOSED LEGISLATION**

80th Oregon Legislative Assembly – 2019 Regular Session  
Legislative Fiscal Office

**Measure: HB 3192**

*Only Impacts on Original or Engrossed  
Versions are Considered Official*

---

Prepared by: Kim To  
Reviewed by: John Borden  
Date: March 21, 2019

---

**Measure Description:**

Imposes annual assessment on manufacture of prescription opioids.

**Government Unit(s) Affected:**

Department of Revenue (DOR), Oregon Board of Pharmacy (OBOP), Oregon Health Authority (OHA)

**Analysis:**

This fiscal impact statement is for the purpose of transmitting the measure from the House Committee on Health Care to the House Committee on Revenue.

The measure imposes an assessment in the amount of \$0.01 per morphine milligram equivalent per year is on each manufacturer of prescription opioids that are dispensed in Oregon, computed based on the prescription opioids dispensed in the state during the previous year by the manufacturer. The bill requires the Department of Revenue, in consultation with the Oregon Health Authority, and the Board of Pharmacy, to determine the morphine milligram equivalents for the prescription opioids dispensed in Oregon, by each registered manufacturer, during the previous year, using information from the prescription monitoring program.

The measure is anticipated to have an impact on the Department of Revenue, the Oregon Health Authority, and the Board of Pharmacy.

A more complete fiscal analysis on the measure will be prepared as the measure is considered in House Committee on Revenue.

Further Analysis Required